Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.

First published in Clinical Pharmacology in Drug Development on 2014 Jul.
Clin Pharmacol Drug Dev. 2014 Jul;3(4):290-6. doi: 10.1002/cpharmacodynamicsd.89. Epub 2014 Feb 17.

Authors: Halabi A, Maatouk H, Siegler KE, Faisst N, Hinrichsen H

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.